Stockscreener 앱 받기
4.03
6.33%
0.24
시간 외 거래:
3.95
-0.08
-1.99%
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Cyclerion Therapeutics (CYCN): ADAR1 Capital discloses 7.0% beneficial ownership - Stock Titan
Cyclerion Therapeutics (CYCN): Balyasny group discloses 7.33% equity position - Stock Titan
Cyclerion (NASDAQ: CYCN) details Korsana merger plans and proxy materials - Stock Titan
Cyclerion Therapeutics (CYCN) outlines two-step merger structure with Korsana Biosciences - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cyclerion Therapeutics (CYCN) outlines terms, risks and disclosures for proposed Korsana merger - Stock Titan
Cyclerion FY26 Q2 net loss widens to $1.76 million; revenue falls to no revenue - Bitget
Cyclerion Therapeutics 2Q 2026: Revenue $0 Net loss $(1.76M) — 10-Q Summary - TradingView
Cyclerion Therapeutics (NASDAQ: CYCN) outlines Korsana merger and going concern risk - stocktitan.net
Cyclerion (CYCN) and Korsana add leaders as reverse merger targets Q3 2026 close - Stock Titan
Cyclerion Therapeutics (CYCN) Slips 1.7% to $3.44 as Consolidation ContinuesIntraday Trade Ideas - dars.gov.et
Cyclerion Therapeutics (CYCN) Stock Slides Slightly as It Tests Key Support LevelRevenue Growth Stocks - dars.gov.et
Cyclerion Therapeutics Inc (CYCN) Institutional Confidence - TradingKey
Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026) - Stock Titan
Cyclerion Therapeutics Inc (CYCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cyclerion Therapeutics Inc (CYCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cyclerion Therapeutics (CYCN) Slides 3.31% as Stock Tests Key Support LevelsRVOL Breakout - po-news-eg.net
Cyclerion Therapeutics, Inc. Revenue Breakdown – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics Inc (CYCN) Balance Sheet - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.370|Chg%:-0.130 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.440|Chg%:-0.060 - TradingKey
CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025 - TradingKey
Cyclerion Therapeutics Inc (CYCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RKLBRocket Lab Stock Price Today, News, Analysis and Trading Ideas - Stocktwits
Cyclerion Therapeutics (CYCN) plans merger with Korsana and $380M financing - Stock Titan
Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com - Investing.com South Africa
Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion - Stock Titan
Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares - Stock Titan
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Tightens Cost ControlProfit Recovery Report - dars.gov.et
Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beat Driven by Disciplined Cost Management, Stock DeclinesDividend Earnings Report - dars.gov.et
Cyclerion Therapeutics (CYCN) Retreats 1.9% as Stock Tests Crucial Support ZoneRVOL Breakout - dars.gov.et
Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal - Stock Titan
Cyclerion Therapeutics to merge with Korsana Biosciences (KRSA) after $380M pre-closing financing - Stock Titan
Cyclerion Therapeutics (CYCN) Presses Lower: Support Test in FocusETF Creation Redemption - dars.gov.et
Cyclerion Therapeutics (CYCN) Gains 6.6% as Shares Test Key Resistance Near $3.55PCR Spike - dars.gov.et
Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Price to sales forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN - TradingView
Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN) - TradingView
Cyclerion Therapeutics (CYCN) Faces Resistance as Shares Slide Nearly 4%Outside Reversal - dars.gov.et
Cyclerion Therapeutics (CYCN) Edges Higher as Stock Tests Key ResistanceIchimoku Cloud - dars.gov.et
Cyclerion Therapeutics Inc (CYCN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cyclerion Therapeutics Inc (CYCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cyclerion Therapeutics, Inc. announced that it has received $200 million in funding - marketscreener.com
Cyclerion Therapeutics (CYCN) Hovers Near $3.00 as Low Volume Caps MovementDark Pool Volume - newsline.com
Cyclerion (NASDAQ: CYCN) to Merge with Korsana, $380M Pre-Closing Financing - Stock Titan
CYCN Q4 2025 Earnings: Narrowed Loss Surpasses Estimates Amid Pipeline ProgressEarnings Outlook Update - newsline.com
Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing - MSN
Cyclerion Therapeutics (CYCN) Edges Higher Amid Quiet TradingCash Flow Strong Stocks - The Legal Advocate
1.80%
1.77%
자본화:
|
볼륨(24시간):